Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
To the Editor:
In the Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack, 1 3 studies, performed in 2107 and 431 patients, respectively, showed no differences between triflusal and aspirin in the prevention of vascular events in patients with stroke or transient ischemic attack, but the hemorrhagic risk was markedly lower with triflusal. The NASPEAF study 4 was a randomized, multicenter clinical trial, performed in 1209 patients with atrial fibrillation that were divided into 2 groups based on risk for thromboembolism: the high-risk group included nonvalvular plus prior embolism and patients with mitral stenosis with and without prior embolism. All others were included in the intermediate-risk The NASPEAF study 4 demonstrated for the first time that the addition of an antiplatelet drug (triflusal) to reduced intensity anticoagulation in atrial fibrillation patients significantly decreases subsequent vascular events compared with patients receiving standard anticoagulation, and does so without increasing bleeding risk.
From the available information, [2] [3] [4] [5] it can be concluded that triflusal has a role in the treatment of patients with ischemic stroke or transient ischemic attack, as well as in patients with atrial fibrillation when combined with reduced intensity anticoagulation.
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